We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against other best small-cap stocks to buy before they explode.
Is Market Volatility Good For Small-Cap Stocks?
Since the announcement of tariffs, investors have been concerned regarding the market volatility. On February 4, 2025, Chris Clark, CEO and Co-CIO of Royce Investment Partners shared his insights as to how this market volatility can be helpful for small-cap stocks. February 2025 saw markets react negatively to President Trump’s announcement of tariffs on imports from China, Canada, and Mexico. Clark emphasized that it is still too early to gauge the positive or negative impacts of these tariffs on earnings and business fundamentals due to the current uncertainty. For instance, while initial announcements caused market disruption, subsequent negotiations led to temporary pauses on tariffs for goods from Mexico and Canada, restoring some measure of calm.
Clark highlighted that tariffs targeting Canada and Mexico appear to address non-economic issues like immigration and drug trade rather than purely economic concerns. This suggests they may be short-lived if their objectives are achieved. However, if sustained, these tariffs could significantly impact sectors such as housing, autos, and agriculture. Despite the disruption caused by these policies, Clark remains optimistic about the opportunities created by elevated market volatility. He argued that such environments allow active investors to distinguish high-quality companies from weaker ones, which he believes is an effective strategy for identifying long-term value amidst short-term uncertainty.
READ ALSO: Top 10 Penny Stocks That Will Skyrocket and 11 Best Extremely Profitable Stocks to Buy According to Analysts.
Clark noted that tariffs will accelerate de-globalization, bring back business to the United States, and improve supply chain management in domestic manufacturing. These factors are anticipated to benefit the potential leadership of US small-cap stocks in the market. Clark cited that small caps have favorable valuations and their earnings are expected to grow. Additionally, the cyclical nature of markets and heightened volatility have historically benefited small-cap stocks relative to large-cap equities. His research shows that following periods of elevated volatility measured by the VIX index, small-cap stocks like those in the Russell 2000 tend to outperform large-cap counterparts over three-year horizons. Clark also stressed the importance of contrarian thinking during uncertain times. Drawing from decades of experience as a small-cap investor, he underscored how understanding market inflection points and challenging conventional wisdom are crucial for achieving long-term outperformance.
Our Methodology
To gather the 10 best small-cap stocks to buy before they explode we used the Finviz stock screener and CNN as our sources. Using the screener we aggregated a list of small-cap stocks (Market Cap of $500 million to $2 billion) with an upside potential of more than 50%. After sorting the list by market capitalization we cross-checked the analysts’ average upside potential of each stock from CNN. Lastly, we ranked these stocks in ascending order of the number of hedge fund holders, sourced from Insider Monkey’s Q4 2024 database. Please note that the data was recorded on March 25, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Market Capitalization: $1.749 Billion
Analyst Upside Potential: 67.13%
Number of Hedge Fund Holders: 33
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company that specializes in the development of transformative therapies for rare genetic diseases, with a strong focus on hemolytic anemias and other genetically defined conditions. It is known for its PYRUKYND, which is a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, approved as the first disease-modifying therapy for hemolytic anemia.
During the fiscal fourth quarter of 2024, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported that it is leveraging its flagship product, PYRUKYND, to target additional rare diseases. It anticipates regulatory approval for thalassemia in September 2025 and a potential launch for sickle cell disease in 2026. It is also enhancing its pipeline and is progressing its early and mid-stage pipeline, for Tebapivat and AG-236.
In 2024, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported a total revenue of $542.3 million, driven by the success of PYRUKYND and other therapies. The fiscal 2025 is expected to be a transformative year for the company as it expects FDA decisions on PYRUKYND for thalassemia, and phase III results for mitapivat in sickle cell disease. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the best small cap stocks to buy before they explode.
Overall, AGIO ranks 3rd on our list of best small-cap stocks to buy before they explode. While we acknowledge the potential of AGIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AGIO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.